PMC:7696151 / 41096-41349 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1149","span":{"begin":58,"end":68},"obj":"Species"},{"id":"1158","span":{"begin":29,"end":32},"obj":"Chemical"},{"id":"1163","span":{"begin":237,"end":252},"obj":"Disease"}],"attributes":[{"id":"A1149","pred":"tao:has_database_id","subj":"1149","obj":"Tax:2697049"},{"id":"A1158","pred":"tao:has_database_id","subj":"1158","obj":"MESH:D006886"},{"id":"A1163","pred":"tao:has_database_id","subj":"1163","obj":"MESH:D008133"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Thus, the ineffectiveness of HCQ antiviral activity again SARS-CoV-2 can be related to the low current dosing regimens and the impossibility to increase the administered doses due to the increased risk of severe side effects, especially QT prolongation."}

{"project":"LitCovid-sentences","denotations":[{"id":"T265","span":{"begin":0,"end":253},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Thus, the ineffectiveness of HCQ antiviral activity again SARS-CoV-2 can be related to the low current dosing regimens and the impossibility to increase the administered doses due to the increased risk of severe side effects, especially QT prolongation."}